These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35772959)

  • 1. Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice.
    Minnix M; Kujawski M; Poku E; Yazaki PJ; Wong JY; Shively JE
    J Nucl Med; 2022 Dec; 63(12):1859-1864. PubMed ID: 35772959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
    Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
    Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
    Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
    Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma.
    Awuah D; Minnix M; Caserta E; Tandoh T; Adhikarla V; Poku E; Rockne R; Pichiorri F; Shively JE; Wang X
    Cancer Immunol Immunother; 2023 Aug; 72(8):2841-2849. PubMed ID: 37209218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of IL-2-antibody to IL-2-Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors.
    Williams L; Li L; Yazaki PJ; Wong P; Hong T; Poku EK; Hui S; Ghimire H; Shively JE; Kujawski M
    Cancer Med; 2024 Feb; 13(3):e6909. PubMed ID: 38317590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
    Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
    Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.
    Kujawski M; Sherman M; Hui S; Zuro D; Lee WH; Yazaki P; Sherman A; Szpikowska B; Chea J; Lasiewski D; Poku K; Li H; Colcher D; Wong J; Shively JE
    Oncoimmunology; 2020; 9(1):1724052. PubMed ID: 32117587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli.
    Bae MY; Cho NH; Seong SY
    Clin Exp Immunol; 2009 Jul; 157(1):128-38. PubMed ID: 19659778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
    Gameiro SR; Higgins JP; Dreher MR; Woods DL; Reddy G; Wood BJ; Guha C; Hodge JW
    PLoS One; 2013; 8(7):e70417. PubMed ID: 23894654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
    Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
    Farsaci B; Higgins JP; Hodge JW
    Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.
    Wu Y; Wan T; Zhou X; Wang B; Yang F; Li N; Chen G; Dai S; Liu S; Zhang M; Cao X
    Cancer Res; 2005 Jun; 65(11):4947-54. PubMed ID: 15930317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen expression of resurgent human colon carcinoma after treatment with therapeutic doses of 90Y-alpha-carcinoembryonic antigen monoclonal antibody.
    Esteban JM; Kuhn JA; Felder B; Wong JY; Battifora H; Beatty JD; Wanek PM; Shively JE
    Cancer Res; 1991 Jul; 51(14):3802-6. PubMed ID: 2065334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model.
    Park JS; Kim HS; Park HM; Kim CH; Kim TG
    Vaccine; 2011 Nov; 29(47):8642-8. PubMed ID: 21945963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.